Back to Agenda
Session 2: Considerations for Process Analytical Technology (PAT) Implementation for Continuous Manufacturing: A Regulatory Perspective
Speaker(s)
Considerations for Process Analytical Technology (PAT) Implementation for Continuous Manufacturing: A Regulatory Perspective
Sharmista Chatterjee, PhD
Office of Pharmaceutical Manufacturing Assessment (OPMA), OPQ/CDER, FDA, United States
Division Director in Division of Pharmaceutical Manufacturing II,
Have an account?
